Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma

Multiple myeloma (MM), the second most common hematopoietic malignancy, remains an incurable plasma cell (PC) neoplasm. While the proteasome inhibitor, bortezomib (Bz) has increased patient survival, resistance represents a major treatment obstacle as most patients ultimately relapse becoming refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Stessman, Holly A. F., Mansoor, Aatif, Zhan, Fenghuang, Linden, Michael A., Van Ness, Brian, Baughn, Linda B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812176/
https://www.ncbi.nlm.nih.gov/pubmed/24204892
http://dx.doi.org/10.1371/journal.pone.0077608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812176/
https://www.ncbi.nlm.nih.gov/pubmed/24204892
http://dx.doi.org/10.1371/journal.pone.0077608

Ejemplares similares